Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients

The Phase 1b assessments of the dose-related safety, PK, and initial antiviral efficacy of
NVR 3-778 in hepatitis B patients will also be conducted at approximately 14 different sites
to meet enrollment goals of 54-84 chronic hepatitis B patients.

To promote objective safety and tolerance assessments during this trial, study subjects, and
site personnel administering the study drug and performing the clinical assessments on the
subjects, will be blinded to individual subjects' treatments assignments (active NVR 3-778 or
placebo doses), for all treatment cohorts in the study. Study advancement to subsequent
patient cohorts will require satisfactory interim reviews of available cumulative safety data
by the Safety Review Committees (SRC), using the safety criteria and review procedures
described in the protocol. Also, there will be one interim review of safety data by an
independent Safety Monitoring Board (SMB), as described in the protocol.

Patients may be male or female between 18 and 65 years of age, with a BMI of 18-35kg/m2.
Patients must be HBeAg positive and have chronic hepatitis B with no history of clinical
decompensation.